Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines

NORIO KONDO 1, MAMORU TSUKUDA 2, ATSUKO SAKAKIBARA 2, HIDEAKI TAKAHASHI 2, HIROSHI HYAKUSOKU 2, MASANORI KOMATSU 2, TATSUO NIHO 2, KOUICHI NAKAZAKI 2 and GABOR TOTH 2

1Department of Otorhinolaryngology, Tama-Hokubu Medical Center, Tokyo; 2Department of Biology and Function in Head and Neck, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Received November 16, 2011; Accepted January 9, 2012

DOI: 10.3892/ijo.2012.1376

Abstract. The epidermal growth factor receptor (EGFR) and related family member, HER-2, are often overexpressed simultaneously in patients with a variety of malignant tumors, and the combination may cooperatively promote cancer cell growth and survival. The purpose of this study was to examine antitumor effects of the combination treatment of cetuximab and trastuzumab on head and neck squamous cell carcinoma (HNSCC) using 16 HNSCC cell lines in terms of antiproliferative effect and antibody-dependent cell-mediated-cytotoxicity (ADCC). Previously we have reported the expression levels of EGFR mRNA on 16 HNSCC cell lines. All cell lines expressed mRNA for EGFR, HER-2 and HER-3; 12 cell lines expressed mRNA for HER-4; and 4 cell lines did not express mRNA for HER-4. In vitro proliferation assay, the combination treatment of cetuximab and trastuzumab significantly lowered cell viability compared to either drug alone. The mRNA expression levels of EGFR and HER-2 were not correlated with the efficacy of the combination treatment of cetuximab and trastuzumab and the expression levels of HER-3 and HER-4 also showed no correlation with the efficacy of the combination treatment. We evaluated the gene status of HER-2 exons 23 and 24 in 16 HNSCC cell lines, but there was no mutation of HER-2 in any of the cell lines. Either drug showed ADCC in the 3 cell lines using peripheral blood mononuclear cells (PBMCs), however, a significant combination effect was not observed. Combined molecular targeted antibody drug therapy for EGFR and HER-2 may be useful in the treatment of HNSCC.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer and 500,000-900,000 HNSCC cases are newly diagnosed annually worldwide (1). The standard treatments for advanced HNSCC include surgery, radiotherapy and chemotherapy. These treatment modalities prolong the survival of individuals with advanced stage HNSCC; however, the treatment benefit is typically temporary in advanced-stage disease (2). Thus, novel and effective antitumor therapies, e.g., targeted molecular therapy, immunotherapy and gene therapy, are necessary for treating advanced HNSCC. Several new molecular-targeted drugs have been studied recently for HNSCC treatment and promising results have been obtained (3-8).

The epidermal growth factor receptor (EGFR) belongs to the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases; this family includes EGFR (ErbB1 or HER-1), HER-2 (ErbB2), HER-3 (ErbB3) and HER-4 (ErbB4). EGFR overexpression has been frequently observed in HNSCC and is thought to be associated with carcinogenesis, metastasis, clinical stage of cancer, and poor prognosis (9,10). HER-2 is a unique receptor since none of the known HER family ligands activate HER-2 homodimers (11). HER-2 appears to function primarily as a heterodimerization partner for other HER family members (12). HER-2 overexpression has been observed in HNSCC (13) and heterodimerization of HER-2 and EGFR is thought to mediate disease progression (14). High expression of EGFR and/or HER-2 has been associated with tumor cell resistance to chemotherapy and radiotherapy (14,15). Therefore, EGFR and HER-2 are attractive targets for anticancer treatment.

Cetuximab (Erbitux®) is a human/murine chimeric IgG1 monoclonal antibody that targets EGFR. Cetuximab binds to the EGFR with a 10-fold higher affinity than the natural ligand of EGFR and prevents ligand-induced phosphorylation in signal cascade pathways. In addition to those mentioned above, other mechanisms of cetuximab-mediated antitumor effect have been proposed. Cetuximab, as an IgG1 monoclonal antibody, exhibits different immunological effect and has potential antitumor activity. Preclinical results have shown that cetuximab can induce either complement-mediated tumor cell killing (CDC) or antibody-dependent cell-mediated-cytotoxicity (ADCC) by interacting with natural killer (NK) cells, monocytes and granulocytes by means of their specific Fc receptors (16,17).

Correspondence to: Dr Norio Kondo, Department of Otorhinolaryngology, Tama-Hokubu Medical Center, 7-1, Aoba-cho 1 chome, Higashimurayama-shi, Tokyo 189-8511, Japan
E-mail: norio_kondo@tahamoku-hp.jp

Key words: EGFR, HER-2, cetuximab, trastuzumab
Trastuzumab (Herceptin®) is a humanized IgG1 monoclonal antibody against the extracellular domain of HER-2. Clinical trials have clearly shown that trastuzumab exhibits significant activity against metastatic breast cancer (18). The mechanisms of trastuzumab antitumor activity induce inactivation of signal transduction (19), the ability to disrupt the heterodimerization of HER-2 with other HER family members (11) and induce immunological responses such as ADCC (19,20).

We previously reported the antitumor effect of combined gefitinib and trastuzumab treatment on HNSCC in vitro (4). In this study, we aimed to determine whether combined cetuximab and trastuzumab treatment exerted antitumor effects, e.g., antiproliferative effect and ADCC, against HNSCC cell lines.

Materials and methods

Drug. Cetuximab (Erbitux®) was provided by Merk Serono (Darmstadt, Germany). Trastuzumab (Herceptin®) was purchased from Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan). For the antiproliferative assays, cetuximab and trastuzumab were diluted with saline and dosing preparations of both agents were prepared on the day of use. Gefitinib (Iressa®) was provided by AstraZeneca (Macclesfield, UK). Dosing preparations of all agents were prepared on the day of use.

Cell lines and culture conditions. Sixteen human HNSCC cell lines were examined in this study. The origins of these cell lines were the oral floor (YCU-OR891), hypopharynx (YCU-H891), mesopharynx (YCU-M862, KCC-M871, and YCU-M941), larynx (KCC-L871, YCU-L891), tongue (KCC-T871, KCC-T873, YCU-T891 and YCU-T892), and maxillary sinus (KCC-SMS871, YCU-MS861), and metastatic tumors from different tongue carcinomas (KCC-TM901, KCC-TM902 and KCC-TM903). These cell lines were established in the Department of Otolaryngology, Yokohama City University School of Medicine and Research Institute, Kanagawa Cancer Center. These cell lines were maintained in RPMI-1640 medium (Life technologies, Inc., Tokyo, Japan) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY), 2 mmol/l L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. These cells were incubated at 37°C in a moist atmosphere containing 5% CO₂.

Detection of HER-2 mutations. Genomic DNA was extracted using SepaGene kit (Sanko Junyaku Co., Ltd., Tokyo, Japan). Exons 23 and 24 of HER-2 gene were amplified by polymerase chain reaction (PCR) using the following primer pairs: HER-2 exon 23, 5'-GCCACGCTCTTCTCAGCTCA-3' and 5'-GCTGAGGTGCTTGTCCTCCTC-3'; HER-2 exon 24, 5'-GCTGAGGTGCTTGTCCTCCTC-3' and 5'-GCTGCACCCTCCTGCTCAGC-3'. The PCR products were further analyzed by direct nucleotide sequencing using ABI PRISM 3100 DNA Analyzer (Applied Biosystems) in order to detect mutations.

Cytotoxic assay. Peripheral blood mononuclear cells (PBMC) were separated from peripheral blood obtained from healthy two donors (donor A and B) by centrifugation with BD Vacutainer® (Becton-Dickinson Co., Franklin Lakes, NJ). Cytotoxicity of PBMC cells were evaluated with LDH release experiments using CytoTox 96® Non-Radioactive Cytotoxicity Assays (Promega, Madison, WI) according to the procedure furnished by producers. Target cells were seeded at a concentration of 1x10⁴ cells/well in 96-well plates. Cetuximab at a concentration of 100 nM and/or trastuzumab (5 wells of the 96-well plate per experimental condition), the cell proliferation was assayed by incubating with Tetra Color One (Seikagaku Co., Ltd., Tokyo, Japan). Relative growth inhibition was calculated by dividing the number of recovered drug-treated cells by the number of vehicle-treated control cells. In case of the combination treatment of cetuximab and trastuzumab, after 72-h exposure to 10 nM cetuximab and/or 0.1 µM trastuzumab (5 wells of the 96-well plate per experimental condition), the cell proliferation was assayed by the same method of trastuzumab alone.

Statistical analysis. For statistical analyses, we used Student's paired t-test. Statistical significance was set at p<0.05.

Results

Expression of HER-2, HER-3 and HER-4 mRNA in 16 HNSCC cell lines. Using real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), we analyzed the steady
The expression of HER-2, HER-3 and HER-4 mRNA varied widely, and all cell lines expressed mRNA encoding HER-2 and HER-3 (Figs. 1 and 2). On the other hand, only 12 cell lines expressed mRNA encoding HER-4 and 4 cell lines did not express HER-4 mRNA (Fig. 3).

In vitro proliferation assay. We evaluated the antiproliferative effect of 0-1 µM trastuzumab on HNSCC cell lines. As shown in Fig. 4, inhibition of trastuzumab-induced cell growth was <25% in all cell lines and the cell viability of almost all cell lines reached a plateau at trastuzumab concentrations of >0.1 µM.

Next, we examined the antiproliferative effect of combined cetuximab (10 nM) and trastuzumab (0.1 µM) treatment on 16 HNSCC cell lines. As shown in Table I, combined cetuximab
and trastuzumab treatment significantly lowered cell viability (% of control) as compared to treatment with cetuximab or trastuzumab alone in 8 HNSCC cell lines.

**Mutation status of HER-2 in 16 HNSCC cell lines.** We investigated the genomic DNA of 16 human HNSCC cell lines by direct sequencing of PCR products using primers designed to amplify the HER-2 exons 23 and 24. No mutation was observed in the HER-2 exons 23 and 24 (NM_001005862 in GenBank) (Table I).

**Correlation between the antiproliferative effect of combined cetuximab and trastuzumab treatment and the mRNA expression of EGFR, HER-2, HER-3 and HER-4.** We have...
previously reported the expression levels of EGFR mRNA in the 16 HNSCC cell lines in a different study (24). To determine the correlation between the antiproliferative effect of combined cetuximab and trastuzumab treatment and the expression of EGFR, we analyzed the levels EGFR mRNA in 16 HNSCC cell lines (Figs. 1-3). On the basis of these results, we analyzed the correlation between HER-2, HER-3 and HER-4 expression and the antiproliferative effect of combined cetuximab and trastuzumab treatment. No correlation was observed (Fig. 5).

Cytotoxicity assay. We evaluated ADCC by peripheral blood mononuclear cells (PBMC) after treatment with cetuximab and trastuzumab alone and combined treatment with cetuximab and trastuzumab by performing lactate dehydrogenase (LDH) release experiments using EGFR high-, HER2 high-(KCC-T873), EGFR low-, HER-2 moderate-(YCU-MS861), EGFR low- and HER-2 low-(YCU-T891)-expressing cells. PBMC used in the experiment were obtained from two healthy donors (donors A and B) (Figs. 6 and 7). Treatment with cetuximab and trastuzumab alone resulted in ADCC in all 3 cell lines in the case of both the donors. However, combined treatment with the drugs did not have a significant effect on all cell lines.

Discussion

Cetuximab has been approved by the food and drug administration (FDA) for clinical use in patients with colorectal cancer and HNSCC. Cetuximab has been established to be clinically effective in phase III trials of colorectal cancer and HNSCC patients; however only 10-20% of the treated patients responded to cetuximab. The primary mechanism of action of cetuximab may involve EGFR blockage. Cetuximab may block the binding of EGFR ligands, e.g., EGF and TGF-α, and prevent ligand-dependent homodimerization, intracellular autophosphorylation and activation of intracellular cascades that control cellular proliferation, adhesion, angiogenesis and apoptosis (25,26). In addition EGFR, HER-2 overexpression is also associated with poor prognosis of carcinoma patients. The humanized anti-HER-2 antibody trastuzumab is effective against metastatic breast cancer (18,27). HER-2 appears to function primarily as a heterodimerization partner for other HER family members (12). EGFR heterodimers produce an intense and sustained proliferative signal that is greater than that of EGFR homodimers (28). Drug-targeting therapy against both EGFR and HER-2 is reported to be effective for breast cancer, non-small cell lung cancer, prostate cancer and vulvar squamous cell carcinoma (29-32). Further, we have
previously reported that HER-targeting therapy with gefitinib and trastuzumab combination is effective for HNSCC in vitro (4). Hence, we examined the antitumor effect of combined treatment with cetuximab and trastuzumab in vitro.

We have previously reported the effect of combined gefitinib and trastuzumab treatment on HNSCC (4). In the present study, we evaluated the antiproliferative effect of trastuzumab alone on the same HNSCC cell lines; the results suggested that trastuzumab alone exerted very few antiproliferative effects on HNSCC (Fig. 4). Further, the antiproliferative effect of trastuzumab alone were weaker than those of cetuximab evaluated by the same method and using the same cell lines (24). In this

Figure 6. Cytotoxic assays in KCC-T873 (EGFR high, HER2 high), YCU-MS861 (EGFR low, HER-2 moderate) and YCU-T891 (EGFR low, HER-2 low). PBMC was extracted from healthy donor A and cytotoxicity assays were performed at different E/T ratios in the presence of cetuximab at a concentration of 100 nM and/or trastuzumab at a concentration of 1 µM. (A) KCC-T873 (EGFR high, HER2 high). (B) YCU-MS861 (EGFR low, HER-2 moderate). (C) YCU-T891 (EGFR low, HER-2 low). Both cetuximab and trastuzumab alone showed ADCC in the 3 cell lines, but significant combination effect was not observed in any experimental model.

Figure 7. Cytotoxic assays in KCC-T873 (EGFR high, HER2 high), YCU-MS861 (EGFR low, HER-2 moderate) and YCU-T891 (EGFR low, HER-2 low). PBMC was extracted from healthy donor B and cytotoxicity assays were performed at different E/T ratios in the presence of cetuximab at a concentration of 100 nM and/or trastuzumab at a concentration of 1 µM. (A) KCC-T873 (EGFR high, HER2 high). (B) YCU-MS861 (EGFR low, HER-2 moderate). (C) YCU-T891 (EGFR low, HER-2 low). Both cetuximab and trastuzumab alone showed ADCC in the 3 cell lines, but significant combination effect was not observed in any experimental model.
study, we combined cetuximab and trastuzumab treatment and obtained significant growth inhibition in 8 out of 16 cell lines (Table I). Therefore, with regard to the antiproliferative effect of drugs on EGFR and HER-2, combined cetuximab and trastuzumab treatment will be effective on HNSCC. However, we found that only 2 cell lines exhibited 50% growth inhibition as compared to controls and the antiproliferative effect of combined treatment was not strong. In our previous study, we had evaluated antiproliferative effect of gefitinib by MTT method using the same 16 cell lines and obtained the IC_{50} values of gefitinib for all cell lines (4). Therefore, combined cetuximab and trastuzumab treatment showed significant antiproliferative effect such as EGFR blockage; however, growth inhibition rate by gefitinib alone was lower as compared to its antiproliferative effect evaluated by the same method using the same HNSCC cell lines (4).

To determine the correlation between the antiproliferative effect of combined cetuximab and trastuzumab treatment and HER expression, we analyzed the levels of HER-2, HER-3 and HER-4 mRNA in 16 HNSCC cell lines (Figs. 1-3). Previously we reported the expression levels of EGFR mRNA in HNSCC cell lines (24). All cell lines expressed mRNA for EGFR, HER-2 and HER-3; 12 cell lines expressed mRNA for HER-4; and 4 cell lines did not express mRNA for HER-4. Probably, the expression of both EGFR and HER-2 is required for the cetuximab and trastuzumab treatment to be effective; however, mRNA expression levels of EGFR and HER-2 were not correlated with the efficacy of combined cetuximab and trastuzumab therapy (Fig. 5A and B). HER-2 appears to function primarily as a heterodimerization partner for other HER family members (12); the expression levels of HER-3 and HER-4 also showed no correlation with the efficacy of combined cetuximab and trastuzumab therapy (Fig. 5C and D).

Cohen et al sequenced the EGFR TK domain and HER-2 in 8 gefitinib-responsive HNSCC patients (33). They did not find any mutation in EGFR but a single mutation was detected in HER-2. Accordingly, the authors suggested that some HNSCC patients responded to gefitinib due to mutations in HER-2 rather than EGFR. In the present study, we did not observe mutation of HER-2 in any cell line, suggesting that the mutation status of HER-2 does not provide any additional information on the efficacy of combined cetuximab and trastuzumab treatment.

The role of IgG1 antibody in the killing of cancer cells by activating CDC and/or ADCC process is well established and experimentally proven. The in vivo antitumor effect of rituximab in B cell lymphoma, trastuzumab in breast and gastric cancer or cetuximab in colon cancer and HNSCC are mainly due to ADCC. These IgG1 monoclonal antibodies induce ADCC by blocking the human Fc receptor, i.e., IgG1 antibody binds the Fc receptors expressed by NK cells, monocytes and granulocytes (17,34). Cetuximab-mediated ADCC has been reported in HNSCC (35-37); we have reported that cetuximab-induced ADCC and the antiproliferative effect by the MTT assay in HNSCC cells (24). However, trastuzumab-mediated ADCC in HNSCC has not been reported yet. Our data show that trastuzumab-induced ADCC by PBMC, obtained from two healthy donors, in all 3 cell lines. Kawaguchi et al reported that the combined cetuximab and trastuzumab therapy induced ADCC in esophageal cancer; however, 1 cell line showed marginal additional effects and 2 cell lines showed no significant effect (38). Similarly, in this study, the combined cetuximab and trastuzumab treatment did not exerted significant additional ADCC in the 3 cell lines as compared to the treatment with cetuximab or trastuzumab alone (Figs. 6 and 7).

On the basis of the reasons stated above, we concluded that the combination treatment with antibodies against both EGFR and HER-2 showed significant additional antiproliferative effect but no additional effect on ADCC. Previously we reported the effect of combined gefitinib and trastuzumab treatment on HNSCC cell lines in vitro (4).

Trastuzumab alone exhibited very slight antiproliferative effect. Combined treatment with antibodies for EGFR and HER-2 showed additional significant effect, but the total antiproliferative effect was not strong. With regard to ADCC, antibodies against EGFR or HER-2 alone exhibited IgG1-mediated ADCC, but the combination treatment had no additional effect. These results suggest that combined treatment with molecular targeted drugs such as TK1 for EGFR and IgG1 antibody for EGFR or HER2 may be effective owing to the antiproliferative effect and ADCC in HNSCC.

Acknowledgements

This study was supported by the Yokohama Foundation for Advancement of Medical Science (N.K.).

References


12. Graus-Porta D, Beerli RR, Daly JM and Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655, 1997.


